Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...

The phase 3 POETYK PsA-1 trial evaluated the drug in patients who were not previously treated with a biologic ...

In its latest update of AXS-05, Axsome reported that the 295-patient phase 3 ACCORD-2 trial met its primary endpoint, with ...

Novo Nordisk has announced an investment of 8.5bn Danish kroner, or approximately $1.2bn, to establish a new rare disease production facility in Odense, Denmark. Construction on the new site, which ...

Technology’s ability to accelerate the pace of innovation while reducing the cost is changing the dynamic of the struggle against cancer in myriad ways The threat of cancer continues to grow as the ...

Merck & Co – known as MSD outside the US and Canada – will be gaining exclusive global rights to Hansoh Pharma’s preclinical GLP-1 candidate in a deal worth over $2bn. The agreement gives Merck a ...

The US Food and Drug Administration (FDA) has approved Organon’s Vtama (tapinarof) cream, 1% to treat atopic dermatitis in adults and children aged as young as two years. The approval comes less than ...

Amgen’s Blincyto (blinatumomab) has been granted a licence extension by the Medicines and Healthcare products Regulatory Agency (MHRA) in acute lymphoblastic leukaemia (ALL). The immunotherapy has ...

Since the Orphan Drug Act was passed in 1983, pharmaceutical companies have increasingly focused on developing treatments for rare diseases. As a result, competition in the rare disease field is ...

Like the ticking of time, the nature of technological advancement is perpetual. Artificial intelligence (AI) is entering the next phase of its ever-evolving journey – revolutionising the way we ...

For most of us working in healthcare communications, the best buzz is when the work has clearly reached those who are most in need of support. For those of us running agencies, it is also very nice ...

At a recent ‘thought shop’, I talked about pleiotropic effects. In biology, this means a gene that produces two unrelated effects but, when applied to business models, it means an organisational ...